CDA and Patent ductus arteriosus: Summary: Lurbinectedin-gemcitabine synergism in PDA models involves lurbinectedin-induced tumor macrophage depletion, triggering CDA downregulation and enhanced DNA damage, supporting the use of this combination to treat macrophage-infiltrated pancreatic tumors.